TLR5信号导致树突细胞功能障碍,并协调免疫检查点治疗对卵巢癌的失败
Mitchell T McGinty1, Audrey M Putelo1, Sree H Kolli1
1Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia.
Cancer immunology research
|February 11, 2025
概括
收费类受体5 (TLR5) 信号阻碍了有效的卵巢癌免疫治疗. 阻断PD-L1/PD-1或CTLA4失败,因为TLR5信号损害了抗瘤T细胞,提供了一个新的治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 微生物学 微生物学
背景情况:
- 卵巢癌是女性癌症死亡的主要原因之一.
- 透瘤的T细胞与卵巢癌患者的更好的生存率相关.
- 目前的免疫疗法,如PD-L1/PD-1和CTLA4阻断,对于卵巢癌通常是无效的.
研究的目的:
- 在卵巢癌中调查PD-L1和CTLA4阻塞失败背后的机制.
- 确定托尔类受体5 (TLR5) 信号在免疫疗法耐药性中的作用.
- 探索克服卵巢癌免疫疗法耐药性的潜在策略.
主要方法:
- 利用卵巢癌的小鼠模型,有或没有TLR5信号.
- 分析免疫细胞种群,包括树突细胞和T细胞,使用流细胞计.
- 研究了TLR5信号对树突细胞分化和功能的影响.
- 在TLR5缺乏的小鼠中评估了Flt3L-Ig与PD-L1阻断结合的疗效.
主要成果:
- 通过细菌鞭激活的慢性TLR5信号,被发现可以控制卵巢癌中PD-L1和CTLA4阻塞的失败.
- TLR5信号破坏了功能IL-12产生XCR1+CD103+常规1型树突细胞的分化.
- 这种损伤导致PD-L1表达髓状细胞的扩张,降低了CD8+ T细胞的激活,并降低了抗瘤免疫力.
- 将Flt3L-Ig与PD-L1阻断相结合,改善了TLR5淘汰小鼠的生存率,但不是在TLR5信号存在的情况下.
结论:
- 慢性TLR5信号传递在CD11c+细胞上是一个关键的宿主内在机制,负责卵巢癌中PD-L1阻断的无效性.
- 针对TLR5信号或增强常规1型树突细胞功能的向可以克服免疫疗法耐药性.
- 这项研究发现了卵巢癌检查点治疗的关键障碍,并提出了一种新的治疗方法.
更多相关视频
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
3.3K
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
6.6K
相关概念视频
Tumor Immunotherapy
464
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
T Cell Types and Functions
938
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
938
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
